Lipopolysaccharide

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PacWest, Integra, and Enviva and Encourages Investors to Contact the Firm

Retrieved on:

Friday, October 20, 2023

In October 2018, the FDA inspected the Boston Facility and found that Integra was in violation of the good manufacturing practice requirements of the Quality System Regulation.

Key Points:

In October 2018, the FDA inspected the Boston Facility and found that Integra was in violation of the good manufacturing practice requirements of the Quality System Regulation.
Most significantly, the FDA found that Integra failed to adequately test for bacterial endotoxins in the medical devices manufactured at the Boston Facility.
The Enviva class action lawsuit alleges that on this news, the price of Enviva common stock fell more than 67%.
For more information on the Enviva class action go to: https://bespc.com/cases/EVA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

Retrieved on:

Thursday, October 19, 2023

Food, Lipopolysaccharide, Prior, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Integra, Pomerantz, LLP, Risk, Patient, Private investigator

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART).

Key Points:

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART).
Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
The investigation concerns whether Integra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

Retrieved on:

Thursday, October 19, 2023

Suite, FDA, Lipopolysaccharide, News, Court, PMA, Integra, GPM, Defendant, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
On this news, Integra’s stock price fell $4.64, or 7.9%, to close at $54.20 per share on April 26, 2023, thereby injuring investors.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

Spectral Medical Announces Opening of Tigris Clinical Trial Site at the Mayo Clinic

Retrieved on:

Monday, October 16, 2023

Randomized controlled trial, Sepsis, Septic shock, Clinical professor, U.S. News & World Report, TSX, Mayo Clinic, News, Mortality, Clinical trial, Lipopolysaccharide, Pharmaceutical industry, Birth control

The Mayo Clinic is a premier medical center in the U.S. and is top ranked in more specialties than any other hospital in the nation, according to U.S. News & World Report.

Key Points:

The Mayo Clinic is a premier medical center in the U.S. and is top ranked in more specialties than any other hospital in the nation, according to U.S. News & World Report.
Dr. John Kellum, Chief Medical Officer of Spectral, commented, “We are pleased to announce the addition of the Mayo Clinic to the premier roster of clinical trial sites participating in Tigris.
Moreover, we are making continued progress enrolling additional sites, and are on track to add an additional six sites in the coming four to six weeks.
We remain highly encouraged by the outlook for the trial, given both the current enrollment rates and preliminary mortality data.”

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PacWest, Integra, and Enviva and Encourages Investors to Contact the Firm

Retrieved on:

Sunday, October 15, 2023

In October 2018, the FDA inspected the Boston Facility and found that Integra was in violation of the good manufacturing practice requirements of the Quality System Regulation.

Key Points:

In October 2018, the FDA inspected the Boston Facility and found that Integra was in violation of the good manufacturing practice requirements of the Quality System Regulation.
Most significantly, the FDA found that Integra failed to adequately test for bacterial endotoxins in the medical devices manufactured at the Boston Facility.
The Enviva class action lawsuit alleges that on this news, the price of Enviva common stock fell more than 67%.
For more information on the Enviva class action go to: https://bespc.com/cases/EVA

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

Retrieved on:

Thursday, October 12, 2023

Integra, GPM, Defendant, Court, FDA, Lipopolysaccharide, News, Suite, PMA, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
On this news, Integra’s stock price fell $4.64, or 7.9%, to close at $54.20 per share on April 26, 2023, thereby injuring investors.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

Retrieved on:

Wednesday, October 11, 2023

Integra, Food, Pomerantz, LLP, Risk, Prior, Lipopolysaccharide, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Patient, Private investigator

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART).

Key Points:

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART).
Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
The investigation concerns whether Integra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PacWest, Integra, and Enviva and Encourages Investors to Contact the Firm

Retrieved on:

Tuesday, October 10, 2023

In October 2018, the FDA inspected the Boston Facility and found that Integra was in violation of the good manufacturing practice requirements of the Quality System Regulation.

Key Points:

In October 2018, the FDA inspected the Boston Facility and found that Integra was in violation of the good manufacturing practice requirements of the Quality System Regulation.
Most significantly, the FDA found that Integra failed to adequately test for bacterial endotoxins in the medical devices manufactured at the Boston Facility.
The Enviva class action lawsuit alleges that on this news, the price of Enviva common stock fell more than 67%.
For more information on the Enviva class action go to: https://bespc.com/cases/EVA

Integra Lifesciences Holdings Corporation (IART) Shareholders Should Contact Robbins LLP for Information About the Class Action Allegations Against Integra Lifesciences Holdings Corporation

Retrieved on:

Wednesday, October 4, 2023

Integra, FDA, Complaint, News, Boston, LLP, Person, PMA, Lipopolysaccharide, SAN, Dietary supplement, Pharmaceutical industry

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points:

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
However, Integra had failed to take sufficient measures to remediate the violations identified by the FDA.
What Now: Similarly situated shareholders may be eligible to participate in the class action against Integra Lifesciences Holdings Corporation.
Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by November 13, 2023.

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Integra LifeSciences Holdings Corporation (IART) Investors and Encourages Investors to Contact the Firm Before November 13, 2023

Retrieved on:

Thursday, October 12, 2023

Class Action Lawsuit, Professional Services, Legal, Integra, Douglas v. U.S. District Court ex rel Talk America, LLP, Court, District court, FDA, Lipopolysaccharide, Kirby, News, Pharmaceutical industry

Investors have until November 13, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points:

Investors have until November 13, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Integra also disclosed declining operating margins for the second quarter of 2023 and flat revenue growth projections, which the Company attributed to the manufacturing stoppage.
On May 23, 2023, Integra announced a recall of all products manufactured at the Company’s Boston facility between March 1, 2018 and May 22, 2023.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.